Otsuka Pharmaceutical Co. Ltd., of Tokyo, reported data from the 48-week ART trial at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2 percent and 53.2 percent respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and/or biologics when treated with between five and eight sessions with Adacolumn.